PBI46 Cost-Effectiveness of Treatment Sequences Initiating with Risankizumab for the Treatment of Moderate to Severe Psoriasis in Portugal
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.124
https://www.valueinhealthjournal.com/article/S1098-3015(20)32380-9/fulltext
Section Title :
Section Order :
10092
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32380-9&doi=10.1016/j.jval.2020.08.124